Oxford BioMedica plc (OXB) Insider Purchases £2,739.24 in Stock
Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 30,436 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was bought at an average price of GBX 9 ($0.12) per share, for a total transaction of £2,739.24 ($3,614.73).
Lorenzo Tallarigo also recently made the following trade(s):
- On Friday, September 22nd, Lorenzo Tallarigo purchased 29,685 shares of Oxford BioMedica plc stock. The stock was bought at an average price of GBX 9 ($0.12) per share, for a total transaction of £2,671.65 ($3,525.53).
Oxford BioMedica plc (LON:OXB) traded down 1.16% during mid-day trading on Monday, reaching GBX 8.50. The company had a trading volume of 4,174,767 shares. Oxford BioMedica plc has a 12-month low of GBX 3.11 and a 12-month high of GBX 11.25. The stock has a 50 day moving average price of GBX 8.91 and a 200-day moving average price of GBX 7.28. The stock’s market capitalization is GBX 262.50 million.
ILLEGAL ACTIVITY WARNING: “Oxford BioMedica plc (OXB) Insider Purchases £2,739.24 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/23/oxford-biomedica-plc-oxb-insider-purchases-2739-24-in-stock.html.
A number of brokerages recently commented on OXB. Peel Hunt began coverage on Oxford BioMedica plc in a research report on Tuesday, September 19th. They issued a “buy” rating and a GBX 13 ($0.17) price target on the stock. Jefferies Group LLC restated a “buy” rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a research report on Thursday, August 31st. N+1 Singer raised their price target on Oxford BioMedica plc from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) and gave the stock a “hold” rating in a research report on Thursday, July 27th. Finally, Shore Capital reaffirmed a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th.
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.